Pharma major Lupin Limited (Lupin) has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic Inderal®-LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin's Pithampur Unit-2 Facility.
Lupin's Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of Inderal®-LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.
Propranolol Hydrochloride Extended-Release (ER) Capsules (Canadian Reference Product: Inderal®-LA Capsules) had an annual sales of approximately CAD 8.6 million (MAT December 2018 IQVIA).
Shares of LUPIN LTD. was last trading in BSE at Rs.763.8 as compared to the previous close of Rs. 759.15. The total number of shares traded during the day was 33312 in over 864 trades.
The stock hit an intraday high of Rs. 766 and intraday low of 753.7. The net turnover during the day was Rs. 25328656.